search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
Outsourcing


Tech transfer: From bottleneck to boon


Outsourcing arrangements have been crucial to the roll-out of Covid-19 vaccines, and the pandemic has focused the industry’s gaze on the importance of broader collaboration, truly effective outsourcing relationships and the need to avoid bottlenecks in the technical transfer phase. Sponsors and CDMOs need to be comfortable sharing the same brain, which means building trust, engaging in full disclosure and creating a platform for collaboration. Jim Banks speaks to Michael Mulkerrin, vice-president and head of CMC at ADC Therapeutics, to find out the ingredients of a smooth technical transfer .


peed has been vital to saving lives during the Covid-19 pandemic, whether in the design of diagnostic tests, the development of vaccines or the delivery of life-saving equipment to hospitals. Speed, though, cannot come at the expense of rigorous research and quality control. Finding the right balance has been hard, but the development and distribution of Covid-19 vaccines have put a spotlight on the pain points that slow down the manufacturing process. Overcoming those problems has led to invaluable insights into pharmaceutical manufacturing and, in particular, how the transfer of technical capabilities to outsourcing partners can be handled better in the future. One of


S 24


the most important realisations has been that, for some of the complex Covid-19 vaccines and biological therapeutics, fast manufacturing requires not only an increased physical production capacity, but also access to knowledge not contained in patents or in other public disclosures. Typically, the need to reverse-engineer originator companies’ manufacturing processes has been a major cause of both expense and delay in the creation of biosimilar products. However, the Covid-19 vaccine development process could herald a more collaborative approach across the industry and a new attitude to how critical technical knowledge is shared.


World Pharmaceutical Frontiers / www.worldpharmaceuticals.net


Parilov/www.shutterstock.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65